• Gamma-interferon-inducible, lysosome/endosome-localized thiolreductase, GILT, has anti-retroviral activity and its expression is counteracted by HIV-1

Kubo, Yoshinao

Izumida, Mai

Yashima, Yuka

Yoshii-Kamiyama, Haruka

Tanaka, Yuetsu

Yasui, Kiyoshi

Hayashi, Hideki

Matsuyama, Toshifumi

    • © 2016 Impact Journals, LLC
    • This article is licensed under a Creative Commons Attribution 3.0 License.
  • Other Antiviral
  • Other Endosome
  • Other Gamma-interferon
  • Other Retroviruses
  • Other Thiolreductase
  • The mechanism by which type II interferon (IFN) inhibits virus replications remains to be identified. Murine leukemia virus (MLV) replication was significantly restricted by γ-IFN, but not human immunodeficiency virus type 1 (HIV-1) replication. Because MLV enters host cells via endosomes, we speculated that certain cellular factors among γ-IFN-induced, endosome-localized proteins inhibit MLV replication. We found that γ-IFN-inducible lysosomal thiolreductase (GILT) significantly restricts HIV- 1 replication as well as MLV replication by its thiolreductase activity. GILT silencing enhanced replication-defective HIV-1 vector infection and virion production in γ-IFNtreated cells, although γ-IFN did not inhibit HIV-1 replication. This result showed that GILT is required for the anti-viral activity of γ-IFN. Interestingly, GILT protein level was increased by γ-IFN in uninfected cells and env-deleted HIV-1-infected cells, but not in full-length HIV-1-infected cells. γ-IFN-induced transcription from the γ-IFNactivation sequence was attenuated by the HIV-1 Env protein. These results suggested that the γ-IFN cannot restrict HIV-1 replication due to the inhibition of γ-IFN signaling by HIV-1 Env. Finally, we found that 4,4'-dithiodipyridine (4-PDS), which inhibits S-S bond formation at acidic pH, significantly suppresses HIV-1 vector infection and virion production, like GILT. In conclusion, this study showed that GILT functions as a host restriction factor against the retroviruses, and a GILT mimic, 4-PDS, is the leading compound for the development of novel concept of anti-viral agents.
  • identifier:Oncotarget, 7(44), pp.71255-71273; 2016
  • identifier:19492553
PublisherImpact Journals LLC
Date Issued 2016-09-18
NIItypejournal article
Identifier URI
  • isIdenticalTo DOI
    • Oncotarget
    7(44), 71255-71273